Event
Neuroscience 2026
Katie Headland
Senior Director | Business Development UK
Hunter Shaw
Director | BD East Coast
The brain remains one of the most challenging frontiers in drug discovery. From understanding disease mechanisms to identifying therapeutic targets, neuroscience research continues to raise new questions and open new possibilities.
This November, Axxam will join the global neuroscience community at Neuroscience 2026, the Society for Neuroscience (SfN) annual meeting in Washington, D.C.
Our colleagues Hunter Shaw, Director BD East Coast, and Katie Headland, Vice President BD & Sales Europe, will attend the conference to exchange perspectives on the evolving challenges of neuroscience research and drug discovery.
From Complex Biology to Meaningful Insights
How can we better capture the complexity of neurological diseases in early drug discovery?
At Axxam, we approach this challenge by combining disease-relevant cellular models with complementary technologies, including high-content imaging, electrophysiology, and functional assays.
From investigating cellular dysfunction to evaluating potential therapeutic compounds, our capabilities help researchers generate meaningful biological evidence and make informed decisions throughout the discovery process.
What challenges are you working on?
Neuroscience 2026 is an opportunity to bring different perspectives together, discuss unresolved questions, and explore new approaches to neurological disease research.
Will you be in Washington, D.C.?
Hunter and Katie would be happy to hear about your research and discuss how Axxam could contribute to your next drug discovery project.